Woodline Partners LP acquired a new stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,535,124 shares of the company's stock, valued at approximately $9,349,000. Woodline Partners LP owned 1.96% of MeiraGTx as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC purchased a new stake in MeiraGTx during the fourth quarter valued at about $459,000. Charles Schwab Investment Management Inc. increased its holdings in shares of MeiraGTx by 13.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 112,021 shares of the company's stock worth $682,000 after buying an additional 12,961 shares during the period. Geode Capital Management LLC increased its holdings in MeiraGTx by 16.4% during the 4th quarter. Geode Capital Management LLC now owns 570,646 shares of the company's stock valued at $3,475,000 after purchasing an additional 80,407 shares during the period. Northern Trust Corp increased its holdings in MeiraGTx by 18.9% during the 4th quarter. Northern Trust Corp now owns 315,665 shares of the company's stock valued at $1,922,000 after purchasing an additional 50,267 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in MeiraGTx by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company's stock valued at $1,429,000 after purchasing an additional 4,186 shares during the period. Institutional investors own 67.48% of the company's stock.
Insider Transactions at MeiraGTx
In related news, CFO Richard Giroux sold 24,000 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $6.00, for a total value of $144,000.00. Following the completion of the transaction, the chief financial officer now directly owns 882,494 shares in the company, valued at $5,294,964. The trade was a 2.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Alexandria Forbes sold 47,500 shares of the business's stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $5.34, for a total transaction of $253,650.00. Following the completion of the transaction, the chief executive officer now owns 1,408,983 shares of the company's stock, valued at approximately $7,523,969.22. The trade was a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.50% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on MGTX. Wall Street Zen downgraded MeiraGTx from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Royal Bank of Canada lifted their price objective on MeiraGTx from $11.00 to $13.00 and gave the company an "outperform" rating in a research report on Monday, March 17th. Finally, Chardan Capital cut their price objective on MeiraGTx from $38.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th.
Read Our Latest Analysis on MeiraGTx
MeiraGTx Stock Up 0.6%
MeiraGTx stock traded up $0.03 during trading hours on Wednesday, hitting $5.12. 99,370 shares of the stock traded hands, compared to its average volume of 362,411. The firm's 50-day moving average price is $5.96 and its two-hundred day moving average price is $6.29. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. The company has a market cap of $411.63 million, a PE ratio of -4.23, a PEG ratio of 0.37 and a beta of 1.30. MeiraGTx Holdings plc has a one year low of $3.85 and a one year high of $8.75.
MeiraGTx (NASDAQ:MGTX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.13). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The firm had revenue of $1.93 million for the quarter, compared to the consensus estimate of $4.44 million. On average, research analysts forecast that MeiraGTx Holdings plc will post -1.48 EPS for the current year.
About MeiraGTx
(
Free Report)
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.
Recommended Stories
Before you consider MeiraGTx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MeiraGTx wasn't on the list.
While MeiraGTx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
